2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

Herrstedt, J.; Clark-Snow, R.; Ruhlmann, C.H.; Molassiotis, A.; Olver, I.; Rapoport, Bernardo Leon; Aapro, M.; Dennis, K.; Hesketh, P.J.; Navari, R.M.; Schwartzberg, L.; Affronti, M.L.; Garcia-Del-Barrio, M.A.; Chan, A.; Celio, L.; Chow, R.; Fleury, M.; Gralla, R.J.; Giusti, R.; Jahn, F.; Iihara, H.; Maranzano, E.; Radhakrishnan, Venkatraman; Saito, Mitsue; Sayegh, Paula; Bosnjak, S.; Zhang, L.; Lee, J.; Ostwal, V.; Smit, T.; Zilic, A.; Jordan, Karin; Scotté, F.

dc.contributor.author	Herrstedt, J.
dc.contributor.author	Clark-Snow, R.
dc.contributor.author	Ruhlmann, C.H.
dc.contributor.author	Molassiotis, A.
dc.contributor.author	Olver, I.
dc.contributor.author	Rapoport, Bernardo Leon
dc.contributor.author	Aapro, M.
dc.contributor.author	Dennis, K.
dc.contributor.author	Hesketh, P.J.
dc.contributor.author	Navari, R.M.
dc.contributor.author	Schwartzberg, L.
dc.contributor.author	Affronti, M.L.
dc.contributor.author	Garcia-Del-Barrio, M.A.
dc.contributor.author	Chan, A.
dc.contributor.author	Celio, L.
dc.contributor.author	Chow, R.
dc.contributor.author	Fleury, M.
dc.contributor.author	Gralla, R.J.
dc.contributor.author	Giusti, R.
dc.contributor.author	Jahn, F.
dc.contributor.author	Iihara, H.
dc.contributor.author	Maranzano, E.
dc.contributor.author	Radhakrishnan, Venkatraman
dc.contributor.author	Saito, Mitsue
dc.contributor.author	Sayegh, Paula
dc.contributor.author	Bosnjak, S.
dc.contributor.author	Zhang, L.
dc.contributor.author	Lee, J.
dc.contributor.author	Ostwal, V.
dc.contributor.author	Smit, T.
dc.contributor.author	Zilic, A.
dc.contributor.author	Jordan, Karin
dc.contributor.author	Scotté, F.
dc.date.accessioned	2024-03-12T07:59:20Z
dc.date.available	2024-03-12T07:59:20Z
dc.date.issued	2024-02
dc.description.abstract	Nausea and vomiting are still considered to be two of the most troublesome adverse events (AEs) for patients treated with antineoplastic therapy. To optimise the utility of available antiemetic prophylaxis, updated reviews of the relevant literature and evidence-based guideline recommendations are crucial. The European Society for Medical Oncology (ESMO) and the Multinational Association of Supportive Care in Cancer (MASCC) completed the fourth Consensus Conference on Antiemetics for the prevention of nausea and vomiting in patients with cancer in Copenhagen in June 2015. This article is an update of the 2015 guidelines.	en_US
dc.description.department	Immunology	en_US
dc.description.librarian	hj2024	en_US
dc.description.sdg	SDG-03:Good heatlh and well-being	en_US
dc.description.sponsorship	Meeting and production costs have been covered by MASCC and ESMO from central funds.	en_US
dc.description.uri	https://www.esmoopen.com	en_US
dc.identifier.citation	Herrstedt, J., Clark-Snow, R., Ruhlmann, C.H. et al. 2024, '2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting', ESMO Open, vol. 9, no. 2, art. 102195, pp. 1-18, doi : 10.1016/j.esmoop.2023.102195.	en_US
dc.identifier.issn	059-7029 (online)
dc.identifier.other	10.1016/j.esmoop.2023.102195
dc.identifier.uri	http://hdl.handle.net/2263/95143
dc.language.iso	en	en_US
dc.publisher	Elsevier	en_US
dc.rights	© 2023 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license.	en_US
dc.subject	Prevention	en_US
dc.subject	Nausea	en_US
dc.subject	Vomiting	en_US
dc.subject	MASCC–ESMO clinical practice guideline	en_US
dc.subject	Radiotherapy	en_US
dc.subject	Chemotherapy	en_US
dc.subject	European Society for Medical Oncology (ESMO)	en_US
dc.subject	Multinational Association of Supportive Care in Cancer (MASCC)	en_US
dc.subject	SDG-03: Good health and well-being	en_US
dc.title	2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting	en_US
dc.type	Article	en_US